LabCorp’s Covance expands clinical research unit in Texas

By Zachary Brennan contact

- Last updated on GMT

Related tags: Medicine, Pharmacology

LabCorp’s Covance expands clinical research unit in Texas
LabCorp’s Covance Drug Development has relocated its clinical research unit (CRU) in Dallas, TX, to a new facility with 28 more medical beds. 

The upgraded facility features more than 55,000 square feet of space, a cGMP pharmacy, dedicated ophthalmology procedure rooms, an advanced telemetry system, and a glucose clamp suite, as well as dedicated screening and outpatient visit areas.

The pharmacy includes three sterile and two non-sterile manufacturing suites, while the telemetry system enables the team to perform continuous data monitoring, supporting improved monitoring of study participants and quick adjustments to treatment regimens, when necessary.

The new unit, which opened earlier this month, also includes a LabCorp patient service center where patients can learn more about volunteering and participating in early stage clinical trials.

Herman Scholtz, VP & General Manager of Early Clinical Services, said: “We have invested in a highly customized facility designed to facilitate the safety and quality of our studies and to enhance our clients’ and volunteers’ experience.”

The Dallas CRU currently employs about 75 medical and professional staff and Covance has plans to expand to 120 employees. Covance has another facility in Alice, Texas where 13 primates died due to overheating​ last year.

The LabCorp acquisition of Covance​ was finalized earlier this year.

Related news

Show more

Related products

show more

A Winning End-to-End Solution for Oncology Studies

A Winning End-to-End Solution for Oncology Studies

Clinical Ink | 22-Feb-2021 | Technical / White Paper

Oncology clinical trials present a unique set of challenges for patients, study sites, and study sponsors. Using electronic patient reported outcomes (ePRO)...

Related suppliers

Follow us


View more